The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression
Open accessAbstract
Parkinson's disease varies widely in clinical manifestations, course of progression and biomarker profiles from person to person. Identification of distinct Parkinson's disease subtypes is of great priority to illuminate underlying pathophysiology, predict progression and develop more efficient personalized care approaches. There is currently no clear way to define and divide subtypes in Parkinson's disease. Using data from the Parkinson's Progression Markers Initiative, we aimed to identify distinct subgroups via cluster analysis of a comprehensive dataset at baseline (i.e. cross-sectionally) consisting of clinical characteristics, neuroimaging, biospecimen and genetic information, then to develop criteria to assign patients to a Parkinson's disease subtype. Four hundred and twenty-one individuals with de novo early Parkinson's disease were included from this prospective longitudinal multicentre cohort. Hierarchical cluster analysis was performed using data on demographic and genetic information, motor symptoms and signs, neuropsychological testing and other non-motor manifestations. The key classifiers in cluster analysis were a motor summary score and three non-motor features (cognitive impairment, rapid eye movement sleep behaviour disorder and dysautonomia). We then defined three distinct subtypes of Parkinson's disease patients: 223 patients were classified as 'mild motor-predominant' (defined as composite motor and all three non-motor scores below the 75th percentile), 52 as 'diffuse malignant' (composite motor score plus either ≥1/3 non-motor score >75th percentile, or all three non-motor scores >75th percentile) and 146 as 'intermediate'. On biomarkers, people with diffuse malignant Parkinson's disease had the lowest level of cerebrospinal fluid amyloid-β (329.0 ± 96.7 pg/ml, P = 0.006) and amyloid-β/total-tau ratio (8.2 ± 3.0, P = 0.032). Data from deformation-based magnetic resonance imaging morphometry demonstrated a Parkinson's disease-specific brain network had more atrophy in the diffuse malignant subtype, with the mild motor-predominant subtype having the least atrophy. Although disease duration at initial visit and follow-up time were similar between subtypes, patients with diffuse malignant Parkinson's disease progressed faster in overall prognosis (global composite outcome), with greater decline in cognition and in dopamine functional neuroimaging after an average of 2.7 years. In conclusion, we introduce new clinical criteria for subtyping Parkinson's disease based on a comprehensive list of clinical manifestations and biomarkers. This clinical subtyping can now be applied to individual patients for use in clinical practice using baseline clinical information. Even though all participants had a recent diagnosis of Parkinson's disease, patients with the diffuse malignant subtype already demonstrated a more profound dopaminergic deficit, increased atrophy in Parkinson's disease brain networks, a more Alzheimer's disease-like cerebrospinal fluid profile and faster progression of motor and cognitive deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
(1970) · Cited by 24,983
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Analysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Smith, A. (2016) · PsycTESTS Dataset · doi:10.1037/t27513-000 · Cited by 1,277
The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument
Stiasny‐Kolster, K., Mayer, G., Schäfer, S., Möller, J. C., Heinzel‐Gutenbrunner, M., & Oertel, W. H. (2007) · Movement Disorders · doi:10.1002/mds.21740 · Cited by 1,060
Visuospatial Judgment: A Clinical Test
Benton, A. L. (1978) · Archives of Neurology · doi:10.1001/archneur.1978.00500300038006 · Cited by 1,012
Stebbins, G. T., Goetz, C. G., Burn, D. J., Jankovic, J., Khoo, T. K., & Tilley, B. C. (2013) · Movement Disorders · doi:10.1002/mds.25383 · Cited by 932
Doty, R. L., Shaman, P., Kimmelman, C. P., & Dann, M. S. (1984) · The Laryngoscope · doi:10.1288/00005537-198402000-00004 · Cited by 878
Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT
Visser, M., Marinus, J., Stiggelbout, A. M., & Van Hilten, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20153 · Cited by 831
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., Starkstein, S., Weintraub, D., Poewe, W., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 683
Fereshtehnejad, S.-M., Romenets, S. R., Anang, J. B. M., Latreille, V., Gagnon, J.-F., & Postuma, R. B. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0703 · Cited by 615
Self-citationNorms for Letter and Category Fluency: Demographic Corrections for Age, Education, and Ethnicity
Gladsjo, J. A., Schuman, C. C., Evans, J. D., Peavy, G. M., Miller, S. W., & Heaton, R. K. (1999) · Assessment · doi:10.1177/107319119900600204 · Cited by 548
Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease
Weintraub, D., Hoops, S., Shea, J. A., Lyons, K. E., Pahwa, R., Driver‐Dunckley, E. D., Adler, C. H., Potenza, M. N., Miyasaki, J., Siderowf, A. D., et al. (2009) · Movement Disorders · doi:10.1002/mds.22571 · Cited by 528
Construct and Concurrent Validity of the Hopkins Verbal Learning Test – Revised
Shapiro, A. M., Benedict, R. H. B., Schretlen, D., & Brandt, J. (1999) · The Clinical Neuropsychologist · doi:10.1076/clin.13.3.348.1749 · Cited by 515
Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Hardy, J., Lang, A. E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25844 · Cited by 506
Self-citationGeriatric Depression Scale (GDS)
(2001) · Management of Dementia · doi:10.3109/9780203213896-32 · Cited by 487
The progression of pathology in longitudinally followed patients with Parkinson’s disease
Halliday, G., Hely, M., Reid, W., & Morris, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0344-8 · Cited by 414
Boeve, B. F., Silber, M. H., Ferman, T. J., Lin, S. C., Benarroch, E. E., Schmeichel, A. M., Ahlskog, J. E., Caselli, R. J., Jacobson, S., Sabbagh, M., et al. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.015 · Cited by 393
Kang, J.-H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3861 · Cited by 367
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub, D., Simuni, T., Caspell‐Garcia, C., Coffey, C., Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26170 · Cited by 305
Postuma, R. B., Gagnon, J. F., Vendette, M., & Montplaisir, J. Y. (2009) · Brain · doi:10.1093/brain/awp244 · Cited by 260
Self-citationNetwork structure of brain atrophy in de novo Parkinson's disease
Zeighami, Y., Ulla, M., Iturria-Medina, Y., Dadar, M., Zhang, Y., Larcher, K. M.-H., Fonov, V., Evans, A. C., Collins, D. L., & Dagher, A. (2015) · eLife · doi:10.7554/elife.08440 · Cited by 238
Self-citationThe identification of Parkinson's disease subtypes using cluster analysis: A systematic review
van Rooden, S. M., Heiser, W. J., Kok, J. N., Verbaan, D., van Hilten, J. J., & Marinus, J. (2010) · Movement Disorders · doi:10.1002/mds.23116 · Cited by 238
Clinical subtypes of Parkinson's disease
van Rooden, S. M., Colas, F., Martínez‐Martín, P., Visser, M., Verbaan, D., Marinus, J., Chaudhuri, R. K., Kok, J. N., & van Hilten, J. J. (2011) · Movement Disorders · doi:10.1002/mds.23346 · Cited by 228
Initiative, T. P. P. M., Kang, J.-H., Mollenhauer, B., Coffey, C. S., Toledo, J. B., Weintraub, D., Galasko, D. R., Irwin, D. J., Van Deerlin, V., Chen-Plotkin, A. S., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1552-2 · Cited by 225
Nalls, M. A., McLean, C. Y., Rick, J., Eberly, S., Hutten, S. J., Gwinn, K., Sutherland, M., Martinez, M., Heutink, P., Williams, N. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00178-7 · Cited by 204
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia
Gomperts, S. N., Locascio, J. J., Rentz, D., Santarlasci, A., Marquie, M., Johnson, K. A., & Growdon, J. H. (2013) · Neurology · doi:10.1212/wnl.0b013e31827b1a07 · Cited by 182
Rolinski, M., Szewczyk-Krolikowski, K., Tomlinson, P. R., Nithi, K., Talbot, K., Ben-Shlomo, Y., & Hu, M. T. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306104 · Cited by 181
Manifestations of Parkinson disease differ in association with REM sleep behavior disorder
Postuma, R. B., Gagnon, J., Vendette, M., Charland, K., & Montplaisir, J. (2008) · Movement Disorders · doi:10.1002/mds.22099 · Cited by 173
Self-citationREM sleep behavior disorder and neuropathology in Parkinson's disease
Postuma, R. B., Adler, C. H., Dugger, B. N., Hentz, J. G., Shill, H. A., Driver‐Dunckley, E., Sabbagh, M. N., Jacobson, S. A., Belden, C. M., Sue, L. I., et al. (2015) · Movement Disorders · doi:10.1002/mds.26347 · Cited by 163
Self-citationAssociation of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease
Kim, J., Oh, Y., Lee, K.-S., Kim, Y.-I., Yang, D., & Goldstein, D. S. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1acd · Cited by 149
Graham, J., & SAGAR, H. J. (1999) · Movement Disorders · doi:10.1002/1531-8257(199901)14:1<10::aid-mds1005>3.0.co;2-4 · Cited by 140
Sieber, B.-A., Landis, S. C., Koroshetz, W. J., Bateman, R. J., Siderowf, A. D., Galpern, W. R., Dunlop, J., Finkbeiner, S. M., Sutherland, M. L., Wang, H., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24261 · Cited by 98
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease
Erro, R., Picillo, M., Vitale, C., Palladino, R., Amboni, M., Moccia, M., Pellecchia, M. T., & Barone, P. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.04.026 · Cited by 76
McMillan, C. T., & Wolk, D. A. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312690 · Cited by 40
Cited by
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Berg, D., Borghammer, P., Fereshtehnejad, S.-M., Heinzel, S., Horsager, J., Schaeffer, E., & Postuma, R. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00486-9 · Cited by 409
Self-citationMitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Metadata
- Authors
- Fereshtehnejad, S.-M., Zeighami, Y., Dagher, A., & Postuma, R. B.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-25
- Volume
- 140
- Issue
- 7
- Pages
- 1959-1976
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2618408467
- Cited by
- 613
- References
- 40
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.